Vaxcyte, Inc.
NASDAQ:PCVX
116 (USD) • At close September 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Vaxcyte, Inc. |
Symbool | PCVX |
Munteenheid | USD |
Prijs | 116 |
Beurswaarde | 14,129,264,000 |
Dividendpercentage | 0% |
52-weken bereik | 44.2 - 119.5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Grant E. Pickering M.B.A. |
Website | https://vaxcyte.com |
An error occurred while fetching data.
Over Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)